The Detailed Disclosure on the facts, is attached.

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com FHL/SEC/2026-27 September 27, 2026 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code: 532843 Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, In furtherance of our earlier disclosures dated September 23, 2022, September 1, 2026 and September, 16, 2026, we would like to inform you that the Hon’ble Supreme Court, vide its order dated 25 September, 2026 (“Order”), has disposed of a Special Leave Petition (“SLP”) filed by the Company challenging the order dated August 31, 2026 passed by the Hon’ble Delhi High Court (“Judgment”) in the matter of Daiichi Sankyo Company, Limited vs. Malvinder Mohan Singh & Ors. The SLP had inter alia challenged the direction for a forensic audit qua the Company contained in the Judgment, as well as certain observations made therein concerning the Company. By way of the Order, the Hon’ble Supreme Court has allowed the forensic audit to proceed, while expressly clarifying that various paragraphs in the Judgment, including certain specific paragraphs identified by the Hon’ble Court, containing observations challenged by the Company, are “tentative and only for the purpose of making out a case for forensic audit.” The Hon’ble Court has further clarified that “It goes without saying that the forensic audit shall be conducted independently, without being influenced by the abovementioned observations.” The Hon’ble Supreme Court has accordingly clarified that the various paragraphs of the Judgment shall not influence the conduct or outcome of the forensic audit, and that the forensic audit is required to be conducted independently of all such observations. Further, as stated in our previous disclosure dated September 1, 2026, the Hon’ble Delhi High Court has not imposed any liability, penalty or fine on the Company. It is extremely important to note that: (i) the Company is a complete stranger to the underlying dispute between Daiichi Sankyo and the Singh Brothers, and accordingly was never a party to the arbitration proceedings between them, and is neither a judgment debtor nor a garnishee in respect of Daiichi Sankyo’s decree; (ii) being a public listed company, the Company had no power or ability to control the transfer of shares by its erstwhile promoters, who were the owners of such shares, and the Company received no monies or proceeds on account of the dissipation of the erstwhile promoters’ shareholding; FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com (iii) following the reduction in the Singh Brothers’ shareholding to less than 1% and their resignation from the Board of Directors by March 2018, the institutional shareholders came together to appoint certain reputable independent directors; (iv) this independent Board, in June 2018, with the guidance of reputable investment bankers and legal advisors, undertook a competitive bidding process to identify and induct a new investor in the Company; and (v) the investment by the Company’s promoter shareholder Northern TK Venture Pte. Ltd., a part of the IHH Healthcare Berhad group, was undertaken through a fresh issuance of equity shares upon receipt of all statutory and regulatory approvals (including from the CCI, SEBI, the stock exchanges and the Company’s shareholders) in November 2018, several months after the Singh Brothers had ceased to have any relationship with the Company, and did not involve any transfer of shares from the Singh Brothers. The Company is confident that an independent forensic audit will attest to the above incontrovertible facts. The Company remains committed to the highest standards of corporate governance, transparency and regulatory compliance and continues to remain focused on its operations and the interests of all its stakeholders, after its successful turnaround since 2018 under its new Promoter shareholder viz. Northern TK Venture Pte. Ltd., a part of the IHH Healthcare Berhad group. The details of the Order, as required to be disclosed under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are attached as Annexure-I. The date and time of occurrence of event is September 26, 2026 at 12:39 PM (IST). This is for your information and records. Thanking You, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer M. No. A14783 Encl :a/a FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com Annexure-I Particulars Details The details of any change in the status The Hon’ble Supreme Court, vide its order dated 25 September, and / or any development in relation to 2026 (“Order”), has disposed of a Special Leave Petition such proceedings (“SLP”) filed by the Company challenging the order dated August 31, 2026 passed by the Hon’ble Delhi High Court (“Judgment”) in the matter of Daiichi Sankyo Company, Limited vs. Malvinder Mohan Singh & Ors. The SLP had inter alia challenged the direction for a forensic audit qua the Company contained in the Judgment, as well as certain observations made therein concerning the Company. By way of the Order, the Hon’ble Supreme Court has allowed the forensic audit to proceed, while expressly clarifying that various paragraphs in the Judgment, including certain specific paragraphs identified by the Hon’ble Court, containing observations challenged by the Company, are “tentative and only for the purpose of making out a case for forensic audit.” The Hon’ble Court has further clarified that “[i]t goes without saying that the forensic audit shall be conducted independently, without being influenced by the abovementioned observations.” Further, as stated in our previous disclosure dated September 1, 2026, the Hon’ble Delhi High Court has not imposed any liability, penalty or fine on the Company. In the case of litigation against key N/A management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings In the event of settlement of the N/A proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933